C07K 14/495
Transforming growth factor [tgf]
Official title: Transforming growth factor [TGF]
C07K14/495 (Transforming growth factor [tgf]) appears on 592 US grants and 767 published applications in this corpus.
Search patents in C07K- Granted patents
- 592
- Published applications
- 767
- Assignees
- 412
- Inventors
- 1,424
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 3 | 0 |
| 1989 | 6 | 0 |
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 10 | 0 |
| 1993 | 10 | 0 |
| 1994 | 10 | 0 |
| 1995 | 15 | 0 |
| 1996 | 12 | 0 |
| 1997 | 20 | 0 |
| 1998 | 38 | 0 |
| 1999 | 22 | 0 |
| 2000 | 18 | 0 |
| 2001 | 22 | 3 |
| 2002 | 21 | 34 |
| 2003 | 21 | 33 |
| 2004 | 14 | 25 |
| 2005 | 8 | 20 |
| 2006 | 14 | 21 |
| 2007 | 6 | 20 |
| 2008 | 8 | 17 |
| 2009 | 11 | 23 |
| 2010 | 9 | 24 |
| 2011 | 11 | 16 |
| 2012 | 11 | 11 |
| 2013 | 8 | 19 |
| 2014 | 11 | 44 |
| 2015 | 24 | 23 |
| 2016 | 11 | 26 |
| 2017 | 26 | 29 |
| 2018 | 15 | 31 |
| 2019 | 20 | 48 |
| 2020 | 21 | 41 |
| 2021 | 26 | 46 |
| 2022 | 21 | 40 |
| 2023 | 20 | 52 |
| 2024 | 24 | 53 |
| 2025 | 22 | 40 |
| 2026 | 15 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oncolytic viruses encoding recombinant transforming growth factor (TGF)-beta monomers and uses thereof15 Sep 2026US 12,735,722 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Activin/BMP7 chimeras: super-active SAB704 and SAB715, and their respective nogginsensitized variants, NAB704 and NAB715; and NAB20414 Jul 2026US 12,679,876 B2OSR Holdings Co., Ltd.
- Combined therapy for muscular diseases9 Jun 2026US 12,649,002 B2Association Institut De Myologie
- Computational design of alpha(v) beta (6) integrin binding proteins19 May 2026US 12,630,584 B2Children's Medical Center Corporation
- Stabilized receptor polypeptides and uses thereof19 May 2026US 12,630,608 B2Amgen Inc.
- Compositions and methods for treating tendon and bone injuries24 Sep 2026US 2026/0284201 A1The Regents of the University of California
- Engineered t cells3 Sep 2026US 2026/0258104 A1Intellia Therapeutics, Inc.
- Use of transforming growth factor beta 1 (tgf-beta1)-overexpressing olfactory mucosa mesenchymal stem cell (om-msc) in preparation of drug for treating parkinson's disease (pd)27 Aug 2026US 2026/0248855 A1Hunan Bizu Biotechnology Co., Ltd.
- Method for suppressing immune responses to transplanted cells, tissues and organs20 Aug 2026US 2026/0240909 A1
- Nucleic Acids Encoding TGF-Beta Inhibitor and IL-12 and Uses Thereof13 Aug 2026US 2026/0234667 A1KaliVir Immunotherapeutics, Inc.
Most cited
By later US patents
- Collagen-polymer conjugates778US 5,162,430 ACollagen Corporation · 1992
- Biologically inert, biocompatible-polymer conjugates521US 5,324,775 ACollagen Corporation · 1994
- Collagen-polymer conjugates471US 5,328,955 ACollagen Corporation · 1994
- Collagen-based bioadhesive compositions288US 5,614,587 ACollagen Corporation · 1997
- Glycosaminoglycan-synthetic polymer conjugates284US 5,510,418 ACollagen Corporation · 1996